Cargando…
Therapeutic effects of D-aspartate in a mouse model of multiple sclerosis
Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis. EAE is mainly mediated by adaptive and innate immune responses that leads to an inflammatory demyelization and axonal damage. The aim of the present research was to examine the therapeutic efficacy of D-asparti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taiwan Food and Drug Administration
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328824/ https://www.ncbi.nlm.nih.gov/pubmed/28911655 http://dx.doi.org/10.1016/j.jfda.2016.10.025 |
_version_ | 1784757803893653504 |
---|---|
author | Afraei, Sanaz D’Aniello, Antimo Sedaghat, Reza Ekhtiari, Parvin Azizi, Gholamreza Tabrizian, Nakisa Magliozzi, Laura Aghazadeh, Zahra Mirshafiey, Abbas |
author_facet | Afraei, Sanaz D’Aniello, Antimo Sedaghat, Reza Ekhtiari, Parvin Azizi, Gholamreza Tabrizian, Nakisa Magliozzi, Laura Aghazadeh, Zahra Mirshafiey, Abbas |
author_sort | Afraei, Sanaz |
collection | PubMed |
description | Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis. EAE is mainly mediated by adaptive and innate immune responses that leads to an inflammatory demyelization and axonal damage. The aim of the present research was to examine the therapeutic efficacy of D-aspartic acid (D-Asp) on a mouse EAE model. EAE induction was performed in female C57BL/6 mice by myelin 40 oligodendrocyte glycoprotein (35-55) in a complete Freund’s adjuvant emulsion, and D-Asp was used to test its efficiency in the reduction of EAE. During the course of study, clinical evaluation was assessed, and on Day 21, post-immunization blood samples were taken from the heart of mice for the evaluation of interleukin 6 and other chemical molecules. The mice were sacrificed, and their brain and cerebellum were removed for histological analysis. Our findings indicated that D-Asp had beneficial effects on EAE by attenuation in the severity and delay in the onset of the disease. Histological analysis showed that treatment with D-Asp can reduce inflammation. Moreover, in D-Asp-treated mice, the serum level of interleukin 6 was significantly lower than that in control animals, whereas the total antioxidant capacity was significantly higher. The data indicates that D-Asp possess neuroprotective property to prevent the onset of the multiple sclerosis. |
format | Online Article Text |
id | pubmed-9328824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taiwan Food and Drug Administration |
record_format | MEDLINE/PubMed |
spelling | pubmed-93288242022-08-09 Therapeutic effects of D-aspartate in a mouse model of multiple sclerosis Afraei, Sanaz D’Aniello, Antimo Sedaghat, Reza Ekhtiari, Parvin Azizi, Gholamreza Tabrizian, Nakisa Magliozzi, Laura Aghazadeh, Zahra Mirshafiey, Abbas J Food Drug Anal Original Article Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis. EAE is mainly mediated by adaptive and innate immune responses that leads to an inflammatory demyelization and axonal damage. The aim of the present research was to examine the therapeutic efficacy of D-aspartic acid (D-Asp) on a mouse EAE model. EAE induction was performed in female C57BL/6 mice by myelin 40 oligodendrocyte glycoprotein (35-55) in a complete Freund’s adjuvant emulsion, and D-Asp was used to test its efficiency in the reduction of EAE. During the course of study, clinical evaluation was assessed, and on Day 21, post-immunization blood samples were taken from the heart of mice for the evaluation of interleukin 6 and other chemical molecules. The mice were sacrificed, and their brain and cerebellum were removed for histological analysis. Our findings indicated that D-Asp had beneficial effects on EAE by attenuation in the severity and delay in the onset of the disease. Histological analysis showed that treatment with D-Asp can reduce inflammation. Moreover, in D-Asp-treated mice, the serum level of interleukin 6 was significantly lower than that in control animals, whereas the total antioxidant capacity was significantly higher. The data indicates that D-Asp possess neuroprotective property to prevent the onset of the multiple sclerosis. Taiwan Food and Drug Administration 2017-03-27 /pmc/articles/PMC9328824/ /pubmed/28911655 http://dx.doi.org/10.1016/j.jfda.2016.10.025 Text en © 2017 Taiwan Food and Drug Administration https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Original Article Afraei, Sanaz D’Aniello, Antimo Sedaghat, Reza Ekhtiari, Parvin Azizi, Gholamreza Tabrizian, Nakisa Magliozzi, Laura Aghazadeh, Zahra Mirshafiey, Abbas Therapeutic effects of D-aspartate in a mouse model of multiple sclerosis |
title | Therapeutic effects of D-aspartate in a mouse model of multiple sclerosis |
title_full | Therapeutic effects of D-aspartate in a mouse model of multiple sclerosis |
title_fullStr | Therapeutic effects of D-aspartate in a mouse model of multiple sclerosis |
title_full_unstemmed | Therapeutic effects of D-aspartate in a mouse model of multiple sclerosis |
title_short | Therapeutic effects of D-aspartate in a mouse model of multiple sclerosis |
title_sort | therapeutic effects of d-aspartate in a mouse model of multiple sclerosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328824/ https://www.ncbi.nlm.nih.gov/pubmed/28911655 http://dx.doi.org/10.1016/j.jfda.2016.10.025 |
work_keys_str_mv | AT afraeisanaz therapeuticeffectsofdaspartateinamousemodelofmultiplesclerosis AT danielloantimo therapeuticeffectsofdaspartateinamousemodelofmultiplesclerosis AT sedaghatreza therapeuticeffectsofdaspartateinamousemodelofmultiplesclerosis AT ekhtiariparvin therapeuticeffectsofdaspartateinamousemodelofmultiplesclerosis AT azizigholamreza therapeuticeffectsofdaspartateinamousemodelofmultiplesclerosis AT tabriziannakisa therapeuticeffectsofdaspartateinamousemodelofmultiplesclerosis AT magliozzilaura therapeuticeffectsofdaspartateinamousemodelofmultiplesclerosis AT aghazadehzahra therapeuticeffectsofdaspartateinamousemodelofmultiplesclerosis AT mirshafieyabbas therapeuticeffectsofdaspartateinamousemodelofmultiplesclerosis |